"Peru Pharmaceuticals & Healthcare Report Q3 2013" Now Available at Fast Market Research
Given that the Peruvian government does not operate a comprehensive medicine pricing system, pharmaceutical companies can generate rapid sales growth, particularly in regards to the country's out-ofpocket spending sector. The strengthening of the nuevo sol will also benefit foreign drugmakers when they repatriate profits generated in Peru to their home countries. However, low per capita spending on drugs, competition from low-cost manufacturers in South America, and the Peruvian government's bias towards non-equivalent generic products all mean multinationals have a weak...
View full press release